Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.

The Prostate
Kristin A RaclawDonald J Tindall

Abstract

Prostate tumors initially regress in response to androgen-ablation therapy. However, most cancers eventually relapse with an androgen-depletion-independent (ADI) phenotype that is often more aggressive than the original androgen-dependent (AD) tumor. Importantly, most relapsed tumors still rely upon androgen receptor (AR) activity for proliferation and survival. The cellular Fas/FasL-associated death domain protein-like inhibitory protein (FLIP) inhibits activation of procaspase-8 by death receptor-mediated signaling at the cell surface. In the current study, we examined the androgenic regulation of FLIP and its contribution to protecting prostate cancer cells from death receptor-mediated apoptosis. FLIP expression in tissues from intact and castrated rats as well as androgen-treated prostate cancer cell lines (LNCaP, C4-2, LNCaP-Rf, and DU-145) was monitored via Real-Time RT-PCR and immunoblot. Induction of apoptosis by TRAIL, the death receptor ligand, was determined via microscopic observation and cell counting of fragmented nuclei following fixation and staining with Hoechst 33285. FLIP mRNA and protein expression was reduced following castration in multiple rat tissues, including dorsolateral prostate and seminal vesicles....Continue Reading

References

Jul 11, 1997·The Journal of Biological Chemistry·S HuV M Dixit
Jul 10, 1997·Nature·M IrmlerJ Tschopp
Mar 30, 2001·The Journal of Biological Chemistry·A NesterovA S Kraft
Jun 18, 2003·Journal of Cellular Physiology·Kent L NastiukJohn J Krolewski
Aug 2, 2003·Molecular and Cellular Endocrinology·Hannelore HeemersJohannes V Swinnen
Dec 23, 2003·Journal of Cellular Biochemistry·Natalya V GusevaMichael B Cohen
Sep 25, 2004·The Prostate·Hiroshi MiyamotoChawnshang Chang
Oct 8, 2004·The New England Journal of Medicine·Jose D Debes, Donald J Tindall
Jan 12, 2005·The Journal of Urology·R E Sobel, M D Sadar
Feb 11, 2005·The Journal of Biological Chemistry·Alexander GolksInna N Lavrik
Apr 19, 2005·Critical Reviews in Immunology·Takao Kataoka
Mar 7, 2006·Journal of Cellular Biochemistry·Scott M Dehm, Donald J Tindall
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Oct 3, 2007·Expert Opinion on Therapeutic Targets·Delphine MérinoOlivier Micheau

❮ Previous
Next ❯

Citations

Aug 28, 2012·Apoptosis : an International Journal on Programmed Cell Death·Claudia GiampietriElio Ziparo
Feb 5, 2011·Molecular Endocrinology·Jennifer S DavisJohn J Krolewski
Jun 15, 2011·Nature Reviews. Urology·Christina Voelkel-Johnson
Jan 3, 2016·Advanced Drug Delivery Reviews·Kent L Nastiuk, John J Krolewski
Jan 11, 2011·Cancer Letters·Marco de BruynWijnand Helfrich
Mar 2, 2021·The Journal of Steroid Biochemistry and Molecular Biology·Iván Flores-RamírezElizabeth Langley
Mar 7, 2021·Cancers·Amaal Ali, George Kulik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis